News

 Array ( [0] => stdClass Object ( [id] => 1196 [id_crawler] => [category_product] => NULL [thumbnail] => gentis-09046.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-03-08 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-03-30 10:35:45 [updated_time] => 2024-09-04 11:37:05 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => the-coffee-talk-genetic-consulting-in-the-field-of-assisted-reproduction-no-1-pgt-expert-consutation [title] => The Coffee Talk: Genetic consulting in the field of assisted reproduction no.1: PGT Expert consultation [description] => et's review the full recording of the Coffee talk program that took place on March 2 No. 01 with the topic: PGT expert consultation [content] => 
✅The event was chaired by Assoc.Prof. Trinh The Son PhD.MD. - Director of the Military Institute of Clinical Embryo-Histology and Nguyen Khac Han Hoan PhD.MD. - Vice Chairman of the Vietnam Association of Medical Genetics - Head of the Department of Medical Genetics Testing, Tu Du Hospital
 
✅And the participation of nearly 50 delegates, who are clinicians, embryologists, genetic physicians and laboratory experts
 
---------
 
???????? This conversation would answer the following questions:
 
❓What is the role of cooperation and coordination between Clinicians, Embryologists, Genetics Doctors, and Laboratory Experts in genetic counseling for patients undergoing HTSS, especially when using PGT testing?
 
❓What is the role of genetic counseling of professional units to provide genetic counseling services for hospitals and clinics?
 
❓What are the difficulties for doctors to correctly prescribe for testing and advise patients before testing?
 
❓What are the difficulties of a clinical doctor after reading the test results?
 
CLICK to watch now with GENTIS!
 [content_more] => [meta_title] => The Coffee Talk: PGT Expert consultation [meta_description] => et's review the full recording of the Coffee talk program that took place on March 2 No. 01 with the topic: PGT expert consultation [meta_keyword] => Gentis,pgt,geneticconsulting [thumbnail_alt] => [post_id] => 1196 [category_id] => 4 ) [1] => stdClass Object ( [id] => 1195 [id_crawler] => [category_product] => NULL [thumbnail] => z5288819335015_afbf0fa01aaac5723f23ea8c8ef85a59.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-03-28 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-03-28 16:49:26 [updated_time] => 2024-09-04 14:04:59 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Rare-diseases-a-major-challenge-for-medicine-in-diagnosis-and-treatment [title] => Rare Diseases - A Major Challenge for Medicine in Diagnosis and Treatment [description] => Genetic disorders, undiagnosed and rare diseases are on the rise globally. According to the World Health Organization, the mortality rate due to congenital anomalies in children under 5 years old in Vietnam in 2015 was 16%, ranking second only to preterm birth. This poses a significant challenge to the goal of reducing child mortality and alleviating the burden on society. [content] => 
This information was shared at the 4th Vietnam - US Conference on Medical Genetics and Rare Diseases, organized by the Vietnam National Hospital of Pediatrics in Hanoi on March 25, 2024.
 
Currently, there are approximately 6,000 known rare diseases affecting 300 million people worldwide - equivalent to the entire population of the United States. Of these, 80% are genetic in origin, with fewer than 200,000 individuals diagnosed. Due to their rarity and complexity, rare diseases present significant challenges for medicine in terms of diagnosis and treatment.
 
The 4th Vietnam - US Conference on Medical Genetics and Rare Diseases attracted the participation of over 300 delegates.
 
In recent years, we have witnessed remarkable technological advancements in the diagnosis and treatment of genetic diseases. Notably, next-generation sequencing (NGS) and enzyme replacement therapy (ERT) have emerged as promising tools. 
 
To provide updates on the latest diagnoses and treatments for genetic and rare diseases in Vietnam and globally, the Vietnam National Hospital of Pediatrics organized the 4th Vietnam - US Conference on Medical Genetics and Rare Diseases.
 
Speaking at the opening ceremony, Mr. Phan Huu Phuc (Deputy Director in charge of medical affairs at the Vietnam National Hospital of Pediatrics) warmly welcomed distinguished guests and colleagues from both within Vietnam and internationally. Mr. Phuc shared: "Medical genetics has been playing a crucial role in both clinical practice and research. Updating knowledge and sharing experiences through scientific conferences like this are essential."
 
Mr. Phan Huu Phuc (Deputy Director in charge of medical affairs at the Vietnam National Hospital of Pediatrics) delivers the opening speech at the conference.
 
Through this conference, Mr. Phuc expressed his hope to foster more opportunities for scientific research collaboration and international cooperation in the field of Pediatrics, aiming to help Vietnamese physicians stay abreast of the latest advancements worldwide.
 
The 4th Vietnam - US Conference on Medical Genetics and Rare Diseases boasts a comprehensive agenda, focusing on five key themes:
 
 
Cancer Genetics and Preimplantation Genetic Testing (PGT)
 
Complete Genome/Exome Sequencing for Rare and Undiagnosed Diseases; Enzyme Replacement Therapy
 
The Power of Complete Genome Sequencing - Discovering Novel Variants in Precision Medicine
 
Training in Medical Genetics; Monogenic Diseases and Gene Therapy
 
Genetic Counseling and Prenatal Diagnosis
 
 
The speakers and chairs participating in the conference are all leading experts with extensive experience in Vietnam, alongside renowned pediatric specialists from the University of Washington. This conference serves as an invaluable opportunity for delegates and physicians to update their knowledge and exchange experiences on cutting-edge techniques implemented in the diagnosis and treatment of genetic and rare diseases.
 
Pham Dinh Minh, representing GENTIS, participates in the conference.
 
As a co-organizer of this year's conference, GENTIS showcased its comprehensive genetic testing ecosystem for the Vietnamese population, utilizing next-generation sequencing technology. Notably, this technology is playing a vital role in assisting clinicians in accurately diagnosing and treating patients with rare diseases.
 
With the goal of providing the best genetic analysis solutions for reproductive health for patients and doctors in Vietnam, GENTIS has continuously researched, developed, and applied PGT-M technology for preimplantation genetic testing for rare diseases. Not only effective in diagnosing Thalassemia, PGT-M also aids in diagnosing many other rare single-gene disorders in embryos, such as spinal muscular atrophy, Duchenne muscular dystrophy, Hemophilia, achondroplasia, congenital adrenal hyperplasia, spherocytosis, Marfan syndrome, autosomal dominant polycystic kidney disease, aniridia, congenital deafness, and more.
 
With a laboratory system that meets ISO 9001:2015 and ISO 15189:2012 standards in Hanoi and Ho Chi Minh City, and the capacity to perform tens of thousands of tests annually, GENTIS remains committed to developing genetic technologies tailored to the Vietnamese population, bringing significant value to the diagnosis and treatment of rare diseases in particular and diseases in general. Notably, GENTIS is increasingly asserting its leading position in the field of genetic analysis, maintaining the complete trust of its valued customers and partners.
 [content_more] => [meta_title] => Rare Diseases - A Major Challenge for Medicine in Diagnosis and Treatment [meta_description] => Genetic disorders, undiagnosed and rare diseases are on the rise globally. [meta_keyword] => assisted reproduction,gentis,rare diseases,pgtm [thumbnail_alt] => [post_id] => 1195 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1194 [id_crawler] => [category_product] => NULL [thumbnail] => gentis-7684.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-03-28 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-03-28 15:27:13 [updated_time] => 2024-09-04 13:58:30 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => The-marvelous-discoverties-of-assisted-reproductive-technology [title] => The Marvelous Discoveries of Assisted Reproductive Technology [description] => The development of the assisted reproductive technology (ART) field has opened a new era for infertile couples. Notably, the success rate of ART techniques is greatly influenced by accompanying technologies such as embryo screening tests and ovarian rejuvenation. [content] => 
GENTIS constantly approaches, researches, and develops new tests, especially clinical applications in ART, to provide accurate, fast, and effective results to help clinicians best treat patients.
 
Prof. Dr. Nguyen Dinh Tao - Chairman of Hanoi Association of ART
 
At the 2nd Scientific Conference and Congress for the 2024-2029 term held on March 24, leading experts updated the latest scientific information in the field of ART.  A highlight was the presentation by MSc. Nguyen Quang Vinh (Director of GENTIS Laboratory Center) on the topic "Application of PGT-Max 1 test in screening embryos carrying common microdeletions."
 
According to MSc. Vinh, PGT-Max 1 is a breakthrough improvement over conventional preimplantation genetic testing (PGT). The advantage of this test is that, in addition to being able to detect aneuploidy of 24 chromosomes, chromosomal structural abnormalities (microdeletions, duplications) with a size of more than 5Mb, and mosaic embryos (20% - 80%), it can also detect additional chromosomal structural abnormalities with a smaller size of more than 2Mb related to some common genetic diseases/syndromes such as:
 
 
22q11.2 deletion (associated with DiGeorge syndrome)
 
1p36 deletion (associated with 1p36 deletion syndrome)
 
Some other common microdeletions/microduplications
 
 
MSc. Nguyen Quang Vinh (Director of GENTIS Laboratory Center) presents on the topic "Application of PGT-Max1 test in screening embryos carrying common microdeletions."
 
GENTIS has successfully optimized and applied the PGT-Max 1 test on embryos for many infertile couples wishing to have children. Thanks to the PGT-MAX 1 test, doctors and experts can select embryos with good genetic quality, increasing the chances of pregnancy when performing in vitro fertilization (IVF), helping children to be born healthy and free from screened genetic abnormalities.
 
At GENTIS, the PGT-MAX 1 test is performed on the most advanced technologies such as NGS sequencers from Illumina USA, specialized bioinformatics software with the highest sensitivity and specificity of up to 99.9%,... "In the future, GENTIS will constantly improve and update new services in the field of assisted reproduction, helping to meet the needs of doctors and help many couples with genetic diseases to give birth to healthy children," MSc. Vinh shared.
 
According to experts, genetic testing is indispensable in assisted reproduction. However, not all clinicians have in-depth expertise in genetics. Therefore, it is difficult to advise patients to understand the method and limitations of genetic testing, explain cases of unsuccessful implementation, or advise on results after implementation, etc.
 
Therefore, the combination of clinicians, testing labs, and geneticists is essential to provide the best advice to patients. These issues were clearly shared by Nguyen Thi Huyen, MSc. MD. in the presentation "Genetic counseling in the era of Genomics and personalized treatment."
 
In the field of ART, genetic counseling plays an extremely important role. Accordingly, geneticists will calculate genetic risks, explain the inheritance pattern of the disease, advise on the principles, advantages, and limitations of testing methods, interpret test results, etc. Thereby, raising awareness and understanding of patients about their genetic risks and making decisions that are beneficial to themselves and their families. 
 
Nguyen Thi Huyen, MSc. MD. presents the report "Genetic counseling in the era of Genomics and personalized treatment"
 
Most importantly, it supports and advises clinicians, helping them to make the best testing and treatment decisions for patients. "With the mission of 'Improving the physical and intellectual well-being of Vietnamese people,' GENTIS always focuses on researching and developing genetic tests serving precision medicine... Thereby bringing modern solutions, accompanying and supporting doctors in taking care of the health of the community," MSc. Huyen shared.
 
Besides, the topic "Ovarian rejuvenation with platelet-rich plasma" by Dr. Dang Vinh Dung (108 Military Central Hospital) is also one of the issues of interest to many experts. According to Dr. Dung, the clinical application of platelet-rich plasma (PRP) has increased markedly in the past decade. PRP therapy is widely used in various fields of medicine, including assisted reproduction. PRP is produced from autologous blood samples with the advantages of being easy to perform, limiting the risk of infectious diseases, and immune reactions.
 
Dr. Dang Vinh Dung (108 Military Central Hospital) presents the report "Ovarian rejuvenation with platelet-rich plasma"
 
PRP therapy is a promising treatment option for women who want to restore or improve ovarian function and rejuvenation. The application of platelet-rich plasma to rejuvenate the ovaries has been applied in the world for about 2-3 years, especially in the last year, there have been many documents talking about this issue and showing very clear results. Dr. Dung also highly appreciated the effectiveness of the PRP IVF kit used to separate platelet-rich plasma that GENTIS is providing.
 
Through the reports at the 2nd Scientific Conference and Congress for the 2024-2029 term, GENTIS hopes to have contributed to providing useful knowledge for doctors and experts in the field of assisted reproduction as well as families wishing to have children. With over 13 years of experience, GENTIS will always develop, innovate, and update the best testing services to customers and partners for the mission of improving the physical and intellectual well-being of Vietnamese people.
 [content_more] => [meta_title] => The Marvelous Discoveries of Assisted Reproductive Technology [meta_description] => The development of the assisted reproductive technology (ART) field has opened a new era for infertile couples [meta_keyword] => assisted reproduction,gentis [thumbnail_alt] => [post_id] => 1194 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1192 [id_crawler] => [category_product] => NULL [thumbnail] => dsc01111.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-03-19 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-03-22 14:17:54 [updated_time] => 2024-10-08 09:00:03 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-a-pioneer-in-PGT-M-in-Vietnam-Screening-for-65-diseases [title] => GENTIS - A Pioneer in PGT-M in Vietnam, Screening for 65 Diseases [description] => Preimplantation Genetic Testing for Monogenic Diseases (PGT-M) combined with In Vitro Fertilization (IVF) has helped couples carrying rare genetic diseases to have healthy babies. GENTIS is proud to be a pioneer in the field of genetic analysis in Vietnam, performing PGT-M for 65 diseases. [content] => 
GENTIS - A reputable organization performing PGT-M for 65 diseases
 
PGT-M is a preimplantation genetic screening for single-gene genetic diseases performed on embryos to screen for embryos that do not carry genetic diseases from their parents for transfer. This test is often indicated for couples carrying mutations that cause genetic diseases who wish to eliminate the disease or mutation in their offsprings. This is a very early screening method, before embryo transfer, so it can help avoid the situation of children being born with the disease as well as reduce the need to terminate pregnancy due to genetic mutations causing serious diseases.
 
Essentially, to perform PGT-M, couples need to undergo IVF to create embryos at Assisted Reproduction Centers. Qualified blastocysts will be biopsied (3-5 embryo cells will be taken from the area that will develop into the placenta later). The biopsied cell samples will be subjected to special testing methods to detect disease-carrying genes.
 
Currently, GENTIS has performed PGT-M screening for 65 single-gene diseases. This is one of the major advantages of GENTIS, which no other organization in Vietnam has achieved.
 
At GENTIS, alongside the application of new technological advancements, the utilization of modern equipment, and specialized analytical software, PGT-M testing is meticulously designed and executed to ensure the highest level of reliability in its results. Notably, GENTIS has currently implemented PGT-M screening for 65 single-gene disorders. This is a significant advantage that sets GENTIS apart as no other facility in Vietnam has achieved this capability.
 
List of 65 diseases that have been performed at GENTIS: What makes PGT-M at GENTIS special?
 
 
 
 
 
 
Number
 
 
 
Diseases' Name
 
 
 
Gene
 
 
 
Genetic Rules
 
 
 
 
 
1
 
 
 
Alpha Thalassemia
 
 
 
HBA1, HBA2
 
 
 
Recessive
 
 
 
 
 
2
 
 
 
Beta Thalassemia
 
 
 
HBB
 
 
 
Recessive
 
 
 
 
 
3
 
 
 
 
Spinal muscle atrophy
 
 
 
 
SMN1
 
 
 
Recessive
 
 
 
 
 
4
 
 
 
 
Duchenne muscular atrophy
 
 
 
 
DMD
 
 
X-linked 
 
 
 
 
 
5
 
 
 
Hemophilia A
 
 
 
F8
 
 
X-linked 
 
 
 
 
 
6
 
 
 
Hemophilia B
 
 
 
F9
 
 
 
X-linked
 
 
 
 
 
7
 
 
 
 
HLA matching
 
 
 
 
HLA
 
 
 
 
 
 
 
 
 
8
 
 
 
 
Congenital adrenal hyperplasia
 
 
 
 
CYP21A2
 
 
 
Recessive
 
 
 
 
 
9
 
 
 
 
Non-syndromic hearing loss
 
 
 
 
GJB2
 
 
 
Recessive
 
 
 
 
 
10
 
 
 
 
Congenital hearing loss
 
 
 
 
GPSM2
 
 
 
Recessive
 
 
 
 
 
11
 
 
 
 
Glucose-6 phosphate dehydrogenase deficiency
 
 
 
 
G6PD
 
 
 
Recessive
 
 
 
 
 
12
 
 
 
 
Phenylketonuria
 
 
 
 
PAH
 
 
 
Recessive
 
 
 
 
 
13
 
 
 
Citrin Deficiency
 
 
 
SLC25A13
 
 
 
Recessive
 
 
 
 
 
14
 
 
 
Wilson desease
 
 
 
ATP7B
 
 
 
Recessive
 
 
 
 
 
15
 
 
 
 
Pompe disease
 
 
 
 
GAA
 
 
 
Recessive
 
 
 
 
 
16
 
 
 
 
Cystic fibrosis
 
 
 
 
CFTR
 
 
 
Recessive
 
 
 
 
 
17
 
 
 
 
Fabry disease
 
 
 
 
GLA
 
 
 
Recessive
 
 
 
 
 
18
 
 
 
 
Galactose metabolism disorder TYPE 1
 
 
 
 
GALT
 
 
 
Recessive
 
 
 
 
 
19
 
 
 
Adrenal leukodystrophy
 
 
 
ABCD1
 
 
 
X-linked
 
 
 
 
 
20
 
 
 
White matter cerebral dystrophy
 
 
 
ISCA2
 
 
 
Recessive
 
 
 
 
 
21
 
 
 
White matter cerebral dystrophy
 
 
 
SETX
 
 
 
Recessive
 
 
 
 
 
22
 
 
 
 
Hypochromic leukodystrophy
 
 
 
 
ARSA
 
 
 
Recessive
 
 
 
 
 
23
 
 
 
5-alpha reductase Deficiency 
 
 
 
SRD5A2
 
 
 
Recessive
 
 
 
 
 
24
 
 
 
 
Spinal muscular atrophy with type I respiratory failure
 
 
 
 
IGHMBP2
 
 
 
Recessive
 
 
 
 
 
25
 
 
 
 
Myotubular myopathy
 
 
 
 
MTM1
 
 
X-linked 
 
 
 
 
 
26
 
 
 
 
Glass bones
 
 
 
 
COL1A1
 
 
 
Dominant
 
 
 
 
 
27
 
 
 
 
Glass bones
 
 
 
 
COL1A2
 
 
 
Dominant
 
 
 
 
 
28
 
 
 
 
Glass bones
 
 
 
 
P3H1
 
 
 
Recessive
 
 
 
 
 
29
 
 
 
Achondroplasia
 
 
 
FGFR3
 
 
 
Dominant
 
 
 
 
 
30
 
 
 
Marfan Syndrome
 
 
 
FBN1
 
 
 
Dominant
 
 
 
 
 
31
 
 
 
Central core myopathy
 
 
 
RYR1
 
 
 
Recessive
 
 
 
 
 
32
 
 
 
 
Muscle weakness
 
 
 
 
COL6A3
 
 
 
Dominant
 
 
 
 
 
33
 
 
 
Jeune Symdrome
 
 
 
DYNC2H1
 
 
 
Recessive
 
 
 
 
 
34
 
 
 
Adams- Oliver Symdrome
 
 
 
DOCK6
 
 
 
Recessive
 
 
 
 
 
35
 
 
 
 
Polycystic kidney disease is dominantly inherited
 
 
 
 
PKD1
 
 
 
Dominant
 
 
 
 
 
36
 
 
 
 
Polycystic kidney disease is dominantly inherited
 
 
 
 
PKD2
 
 
 
Dominant
 
 
 
 
 
37
 
 
 
 
Atypical hemolytic-uremic syndrome
 
 
 
 
CFH
 
 
Dominant-Recessive 
 
 
 
 
 
38
 
 
 
 
Renal tubular dysfunction
 
 
 
 
ACE
 
 
 
Recessive
 
 
 
 
 
39
 
 
 
Alport Symdrome
 
 
 
COL4A5
 
 
 
X-linked
 
 
 
 
 
40
 
 
 
 
Hemophagocytic syndrome
 
 
 
 
PRF1
 
 
 
Recessive
 
 
 
 
 
41
 
 
 
 
Hemophagocytic syndrome
 
 
 
 
STXBP2
 
 
 
Recessive
 
 
 
 
 
42
 
 
 
 
Colon adenopathy
 
 
 
 
PAX7
 
 
 
Recessive
 
 
 
 
 
43
 
 
 
 
Harlequin ichthyosis
 
 
 
 
ABCA12
 
 
 
Recessive
 
 
 
 
 
44
 
 
 
 
Atopic dermatitis
 
 
 
 
FLG
 
 
 
Recessive
 
 
 
 
 
45
 
 
 
 
Familial hypercholesterolemia
 
 
 
 
LDLR
 
 
 
Dominant
 
 
 
 
 
46
 
 
 
 
Cardiac muscle relaxation
 
 
 
 
NEXN
 
 
 
Recessive
 
 
 
 
 
47
 
 
 
Brugada Symdrome
 
 
 
SCN5A
 
 
 
Dominant
 
 
 
 
 
48
 
 
 
Carnitine Acyltransferase Transferase (CACT) deficiency
 
 
 
SLC25A20
 
 
 
Recessive
 
 
 
 
 
49
 
 
 
 
Neonatal diabetes
 
 
 
 
ABCC8
 
 
 
Recessive
 
 
 
 
 
50
 
 
 
Neurofibromatosis
 
 
 
NF1
 
 
 
Dominant
 
 
 
 
 
51
 
 
 
Bohring-Optiz Symdrome
 
 
 
ASXL1
 
 
 
Recessive
 
 
 
 
 
52
 
 
 
NooNan 1 Symdrome
 
 
 
PTPN11
 
 
 
Dominant
 
 
 
 
 
53
 
 
 
NooNan 4 Symdrome
 
 
 
SOS1
 
 
 
Dominant
 
 
 
 
 
54
 
 
 
NooNan 5 Symdrome
 
 
 
RAF1
 
 
 
Dominant
 
 
 
 
 
55
 
 
 
 
Kalman syndrome
 
 
 
 
VPS33B
 
 
 
Recessive
 
 
 
 
 
56
 
 
 
 
Kalman syndrome
 
 
 
 
PROKR2
 
 
 
Dominant
 
 
 
 
 
57
 
 
 
Psychomotor disorders (EKD1)
 
 
 
PRRT2
 
 
 
Dominant
 
 
 
 
 
58
 
 
 
mucolipidosis II alpha/beta
 
 
 
GNPTAB
 
 
 
Recessive
 
 
 
 
 
59
 
 
 
 
Bipotent protein-D protein deficiency)
 
 
 
 
HSD17B4
 
 
 
Recessive
 
 
 
 
 
60
 
 
 
Transthyretin amyloidosis
 
 
 
TTR
 
 
 
Dominant
 
 
 
 
 
61
 
 
 
Aniridia (iridia)
 
 
 
PAX6
 
 
 
Dominant
 
 
 
 
 
62
 
 
 
Mitochondrial disorders
 
 
 
SARS2
 
 
 
Recessive
 
 
 
 
 
63
 
 
 
 
Hereditary cancer
 
 
 
 
MLH1
 
 
 
Dominant
 
 
 
 
 
64
 
 
 
 
Chronic granuloma
 
 
 
 
CYBB
 
 
X-linked 
 
 
 
 
 
65
 
 
 
 
Tuberous sclerosis



TSC1


Dominant




The speciality of GENTIS's PGT-M tests. 
As a pioneer in the field of genetic analysis, GENTIS is always researching and implementing the most advanced gene testing in personalized infertility treatment around the world, including PGT-M. Since 2017, GENTIS has performed over 500 cycles with over 2000 embryos for PGT-M Thalassemia, including both alpha Thalassemia and beta Thalassemia.
Of these, 8 cases with 44 embryos have been performed in combination with PGT-M for Thalassemia and HLA matching between the embryo and a sick child in the family. The goal is to store umbilical cord blood cells after the baby is born for hematopoietic stem cell transplantation for the sick baby.




GENTIS brings together a team of personnel with expertise and experience in performing PGT in general and PGT-M in particular
For rare diseases PGT-M, GENTIS has performed 94 cycles with a total of 434 embryos. To achieve these achievements, GENTIS has:
* Assembled a team of personnel with expertise and experience in performing PGT in general and PGT-M in particular.
* Equipped with a full system of machinery, equipment and laboratories, meeting the stringent requirements of the test.
* Has a full range of tests from screening for disease-causing mutations in parents and family members to screening for embryos based on the results of the parents' tests.
* Has a team of genetic counselors before, during and after testing.
With the rapid development of modern technology, GENTIS will continue to research and implement PGT-M for other rare genetic diseases, contributing to the success of pre-implantation screening and bringing healthy babies to families.
            [content_more] => 
            [meta_title] => GENTIS - A Pioneer in PGT-M in Vietnam, Screening for 65 Diseases
            [meta_description] => Preimplantation Genetic Testing for Monogenic Diseases (PGT-M) combined with In Vitro Fertilization (IVF) has helped couples carrying rare genetic diseases to have healthy babie
            [meta_keyword] => Gentis,PGT-m
            [thumbnail_alt] => 
            [post_id] => 1192
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1191
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z5254489435139_77cf34b1509611521de1946265081e11.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2024-03-16
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-03-18 08:37:02
            [updated_time] => 2024-09-04 09:20:28
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-attending-the-grand-opening-of-Phuong-Nam-Hospital
            [title] => GENTIS attending the Grand Opening of Phuong Nam Hospital
            [description] => On March 16th, 2024, representatives from GENTIS, Mr. Do Manh Ha (General Director) and Mrs. Tran Thi Ha Dong (Deputy Director of the branch) visited and sent warmest congratulations and flowers on the official Grand Opening of Phuong Nam Hospital - a member of Phuong Chau Healthcare Group, located at No.2 Nguyen Luong Bang Street, Tan Phu Ward, District 7, Ho Chi Minh City.

            [content] => 

Phuong Nam Hospital was founded with the mission to deliver high-quality, international-standard healthcare services to the community. With a comprehensive ecosystem encompassing Obstetrics and Gynecology, Pediatrics, Infertility and IVF, General Medicine and Andrology, the hospital is dedicated to play an important role in multidisciplinary consultations and treatments with a closely linked process, fully supporting women's reproductive health issues and families.

With advanced medical facilities and modern infrastructure, as well as a team of experienced doctors and nurses, Phuong Nam Hospital is dedicated to providing patients with the highest quality and safest healthcare services.
GENTIS wishes Phuong Nam Hospital a successful start and sustainable development. Let's take a moment to appreciate the highlights of this special day. 

Với hệ thống trang thiết bị hiện đại, cơ sở vật chất khang trang cùng đội ngũ y bác sĩ giàu kinh nghiệm. Bệnh viện Phương Nam cam kết mang đến dịch vụ chăm sóc sức khỏe chất lượng và an toàn nhất cho quý khách hàng. 
GENTIS chúc bệnh viện có khởi đầu thuận lợi, phát triển vững bền. Hãy cùng GENTIS ngắm nhìn những khoảnh khắc ý nghĩa trong buổi khai trương này nhé!




            [content_more] => 
            [meta_title] => GENTIS attending the Grand Opening of Phuong Nam Hospital
            [meta_description] => On March 16th, 2024, representatives from GENTIS, Mr. Do Manh Ha (General Director) and Mrs. Tran Thi Ha Dong (Deputy Director of the branch) visited and sent warmest congratulations and flowers on the official Grand Opening of Phuong Nam Hospita
            [meta_keyword] => Gentis,Phuongnam,Grandopening
            [thumbnail_alt] => 
            [post_id] => 1191
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1190
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z5251747085819_5ca96fbffed25d32261ac170b459ebfc.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2024-03-15
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-03-15 15:30:54
            [updated_time] => 2024-09-04 09:15:02
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-partners-with-the-scientific-conference-and-the-2nd-congress-term-2024-2029
            [title] => GENTIS Partners with the Scientific Conference and the 2nd Congress, term 2024-2029
            [description] => Following the success of prior scientific conferences, the Hanoi Reproductive Support Association will kick off 2024 with the 2nd Scientific Conference and Congress for the 2024-2029 term. The event will be officially held on March 24, 2024 at the Pan Pacific Hanoi Hotel (No.1 Thanh Nien Street, Truc Bach Ward, Tay Ho District).

            [content] => 
The theme of the conference and the 2nd Congress for the 2024-2029 term is “Discovering the Wonders of Assisted Reproductive Technology.” This event will serve as a platform for clinicians, embryologists, and laboratory specialists to share knowledge, experiences, and the latest advancements, paving the way for new developments in Vietnam's IVF field.

GENTIS proudly presented two scientific papers at the event, providing delegates with access to the latest knowledge and technologies in the field of assisted reproduction:

Application of PGT MAX 1 test in screening of embryos that contain common microdeletion - Nguyen Quang Vinh, MSc.MD., Director of GENTIS Laboratory Center
Genetic counseling in the era of genomics and personalized treatment - Nguyen Thi Huyen, MSc.MD. (GENTIS R&D Consultant)


With genetic technology solutions including PGT MAX 1, PGT-A/SR, PGT-M, ASEM test, ..., GENTIS is dedicated to partnering with hospitals and reproductive centers nationwide to further drive the advancement of IVF in Vietnam.

Additionally, GENTIS will also be showcasing a range of genetic testing services for the assisted reproduction field at our booth. We aim to provide delegates and physicians with the latest knowledge and technological advancements in this field.
We cordially invite all delegates and doctors to attend the scientific conference and visit the GENTIS booth to learn about the latest advanced genetic testing and receive appealing gifts. We look forward to welcoming Delegates and Doctors!
            [content_more] => 
            [meta_title] => GENTIS Partners with the Scientific Conference and the 2nd Congress, term 2024-2029
            [meta_description] => the Hanoi Reproductive Support Association will kick off 2024 with the 2nd Scientific Conference and Congress for the 2024-2029 term
            [meta_keyword] => GENTIS,partner,congress
            [thumbnail_alt] => 
            [post_id] => 1190
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1189
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc01114.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2024-03-15
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-03-15 10:52:38
            [updated_time] => 2024-09-04 14:17:03
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => ASEM-Test-A-valuable-tool-in-assisted-reproduction
            [title] => ASEM Test - A Valuable Tool in Assisted Reproduction
            [description] => In vitro fertilization (IVF) is currently recognized as one of the most effective and widely used treatments for infertility. To support this technique, numerous new technologies have been developed and applied in clinical practice. Among these, the Analysis of Spent Embryo Medium (ASEM) test, which analyzes the DNA present in the embryo culture medium, has garnered significant attention. This method has been shown to significantly improve pregnancy rates, increase the success of IVF, and reduce the risk of miscarriage.

            [content] => 
Overview of the ASEM Test
Chromosomal aneuploidy is a relatively common condition in human embryos, with rates ranging from 20% to 80% depending on maternal age. Approximately 10% of clinical pregnancies are found to have triploidy or monosomy, and this rate can rise to 50% in older pregnant women. Aneuploidy can lead to implantation failure or be a major cause of recurrent miscarriage.
The ASEM test evaluates the chromosomal genetic status of embryos through the embryo culture medium. 
Preimplantation Genetic Testing for Aneuploidy (PGT-A) is currently recommended for couples undergoing IVF to select embryos without chromosomal aneuploidy for transfer. 
PGT-A has been shown to increase successful embryo transfer rates, shorten the time to conception through euploid embryo transfer, and reduce the number of transfers, miscarriage rates, and overall costs, especially in older women. To perform PGT-A, embryo biopsy is required to obtain the necessary material for testing.
In contrast, the ASEM test (Analysis of Spent Embryo Medium) assesses the chromosomal genetic status of embryos through the embryo culture medium without requiring an embryo biopsy. The ASEM test is based on the presence of cell-free DNA (cfDNA) in the culture medium. Studies have shown that blastocyst culture medium can be used to evaluate the genetic status of embryos.
Advantages of the ASEM Test
Because the ASEM test is performed on the embryo culture medium, it is non-invasive and safe. 
Unlike traditional methods that require embryo biopsy, the ASEM test offers several notable advantages:

Reduced Costs: It eliminates the need for equipment investment for embryo biopsy and the requirement for skilled embryologists to perform the biopsy.
Non-Invasive: The ASEM test does not disturb the embryo, which is particularly beneficial for poorly developing embryos where biopsy could be detrimental. It allows for the assessment of chromosomal aneuploidy before embryo transfer without invasive procedures.
Useful in Certain Situations: In cases where embryo biopsy for PGT-A cannot be performed for various reasons, the ASEM test provides valuable genetic information about the embryo.

The Role of the ASEM Test in Assisted Reproduction
The ASEM test represents a breakthrough in genetic diagnosis and is a valuable tool in the field of assisted reproduction. When combined with morphological evaluation, it helps select embryos with the best potential for transfer in cases where embryo biopsy for PGT-A is not feasible. The goal is to increase the success rates of embryo transfers and reduce miscarriage rates for infertile couples.
ASEM Testing at GENTIS

GENTIS is the first institution in Vietnam to implement and offer the ASEM test. Mr. Nguyen Quang Vinh, MSc, Director of the GENTIS Testing Center, stated: "GENTIS continues to research and evaluate the effectiveness of the ASEM test to improve the quality of IVF/ICSI cycles, with the aim of enhancing successful embryo transfer rates."
To assess the clinical effectiveness of the ASEM test, GENTIS has collaborated with several hospitals and assisted reproduction centers nationwide. Notably, GENTIS and Hanh Phuc International Hospital conducted a study titled "Evaluation of the Effectiveness of Genetic Analysis of Embryo Culture Medium." 
The study compared clinical outcomes between two groups: one that selected embryos for transfer based solely on morphological evaluation (control group) and another that used both morphological evaluation and ASEM test results (study group). The study found live birth rates of 38.6% in the control group and 41.1% in the study group. Additionally, the miscarriage rate in the study group was 0% (no miscarriages were recorded) compared to 12.9% in the control group.
These preliminary findings suggest that the ASEM test has the potential to increase live birth rates and significantly reduce miscarriage rates. This is crucial in preventing the physical and emotional trauma associated with miscarriage.
The initial successes of the ASEM test further solidified GENTIS’s leading position in the field of genetic analysis in Vietnam. GENTIS hopes that the ASEM test will become a routine clinical practice in hospitals and IVF centers worldwide, bringing joy and happiness to couples of reproductive age who need medical assistance to conceive and give birth to healthy babies.

            [content_more] => 
            [meta_title] => ASEM Test - A Valuable Tool in Assisted Reproduction
            [meta_description] => n vitro fertilization (IVF) is currently recognized as one of the most effective and widely used treatments for infertility
            [meta_keyword] => asem test,gentis
            [thumbnail_alt] => 
            [post_id] => 1189
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1186
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 2024/03_bvdk_ngoc_bich/9.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2024-03-07
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-03-07 15:30:43
            [updated_time] => 2024-09-04 11:24:22
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 0
            [language_code] => en
            [slug] => Seminar-on-gentis-testing-services-updates-at-ngoc-bich-general-hospital
            [title] => Seminar on GENTIS Testing Services Updates at Ngoc Bich General Hospital
            [description] => On the afternoon of March 6, 2024, GENTIS successfully collaborated with Ngoc Bich General Hospital to host a seminar aimed at updating GENTIS testing services for the hospital's medical staff.

            [content] => 

To foster cooperation and advance research on a range of new services, GENTIS organized the seminar at Ngoc Bich General Hospital in Nam Dinh. The event featured the participation of Dr. Nguyen Van Hoa, Chief Medical Officer; Dr. Nguyen Van Hung, Deputy Director of the hospital; Dr. Vu Duy Trong, Deputy Head of Surgery; Mr. Tran Minh Chau, Head of the Planning Department; along with over 20 other doctors and medical staff from the hospital. GENTIS was represented by Ms. Le Thi Hong Nhung from the product management department.

During the seminar, presenter Le Thi Hong Nhung provided a detailed report on various tests currently being researched and developed by GENTIS. These tests have significant implications in the fields of reproductive health, obstetrics, and pediatrics, and include:
- Non-Invasive Prenatal Testing (NIPT) - GenEva
- Newborn Screening
- Thalassemia Testing
- Thrombophilia Testing
- Antiphospholipid Syndrome Testing
- HPV Testing - EPREP

The seminar began with a comprehensive presentation by Ms. Hong Nhung on GENTIS's GenEva NIPT, a non-invasive prenatal screening test. This test can detect chromosomal abnormalities in fetuses, such as Down syndrome, Edwards syndrome, Patau syndrome, and microdeletions/microduplications.
The test is performed through maternal blood sampling, ensuring safety for both the mother and the fetus. The testing process is optimized, fast, and provides results with an accuracy rate of over 99%.

Additionally, the newborn screening tests offered by GENTIS garnered significant interest from the attending medical staff. Newborn screening is regarded as one of the most effective methods for early detection of abnormalities in infants, allowing for timely intervention and preventing severe complications and damage.
Moreover, newborn screening increases survival rates, reduces the impact of diseases, extends patient lifespans, and helps save on healthcare costs.

As part of the seminar, Ms. Hong Nhung also presented on tests for Thalassemia, Thrombophilia, Antiphospholipid Syndrome, HPV - EPREP, and more.

During the seminar, the doctors, nurses, and medical staff had their questions and concerns addressed directly and thoroughly by Ms. Hong Nhung. The seminar concluded successfully



Following this service update seminar at Ngoc Bich General Hospital, GENTIS hopes that the medical staff have gained valuable information to better advise their patients, ultimately reducing the birth of children with diseases, easing the burden on families and society, and bringing happiness to families across Vietnam.
            [content_more] => 
            [meta_title] => Seminar on GENTIS Testing Services Updates at Ngoc Bich General Hospital
            [meta_description] => On the afternoon of March 6, 2024, GENTIS successfully collaborated with Ngoc Bich General Hospital to host a seminar aimed at updating GENTIS testing services for the hospital's medical staff.

            [meta_keyword] => Gentis,NgocBichGeneralHospital
            [thumbnail_alt] => 
            [post_id] => 1186
            [category_id] => 4
        )

)